TY - JOUR
T1 - Vaccine safety in children with genetically confirmed mitochondrial disease
AU - de Vreugd, Annemarie
AU - Zimmermann, Franz A.
AU - Steinbruecker, Katja
AU - de Vries, Maaike C.
AU - de Boer, Lonneke
AU - Janssen, Mirian C. H.
AU - Huemer, Martina
AU - Wortmann, Saskia B.
N1 - Zimmermann, Steinbrücker, Wortmann: University Children’s Hospital Salzburg, Paracelsus Medical University (PMU), Salzburg, Austria
PY - 2025/2
Y1 - 2025/2
N2 - We here explore adverse events following immunization (AEFI) in children with mitochondrial disease (MD) recruited from two expertise centers in Austria (SALK) and The Netherlands (RUMC). Parents completed a questionnaire on the type of immunizations received and AEFI in a post-vaccination exposure period of seven days. 95 individuals were invited to this study, of whom 30 (median age 13.4 years) participated. Together these individuals had received 376 immunizations with a median of 12 vaccinations each. In 316 of 376 (84 %) vaccinations no AEFI occurred, 22 patients (73 %) never experienced any AEFI. Eight patients experienced 76 AEFI after 60 vaccinations, these were mild (redness (n = 9) /pain at injection site (n = 21), fever (n = 44), gastrointestinal complaints (n = 2)). None had a metabolic deterioration or seizures, no patient was admitted to the hospital. Although our data is limited by the small sample size, this may aid in discussing responsible immunization decisions with parents.
AB - We here explore adverse events following immunization (AEFI) in children with mitochondrial disease (MD) recruited from two expertise centers in Austria (SALK) and The Netherlands (RUMC). Parents completed a questionnaire on the type of immunizations received and AEFI in a post-vaccination exposure period of seven days. 95 individuals were invited to this study, of whom 30 (median age 13.4 years) participated. Together these individuals had received 376 immunizations with a median of 12 vaccinations each. In 316 of 376 (84 %) vaccinations no AEFI occurred, 22 patients (73 %) never experienced any AEFI. Eight patients experienced 76 AEFI after 60 vaccinations, these were mild (redness (n = 9) /pain at injection site (n = 21), fever (n = 44), gastrointestinal complaints (n = 2)). None had a metabolic deterioration or seizures, no patient was admitted to the hospital. Although our data is limited by the small sample size, this may aid in discussing responsible immunization decisions with parents.
KW - Adverse effect
KW - Adverse events following immunization (AEFI)
KW - Epilepsy
KW - Immunization
KW - Metabolic deterioration
KW - Seizure
KW - Side effect
KW - Vaccination
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001363637100001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1016/j.imlet.2024.106946
DO - 10.1016/j.imlet.2024.106946
M3 - Original Article
C2 - 39557131
SN - 0165-2478
VL - 271
JO - IMMUNOLOGY LETTERS
JF - IMMUNOLOGY LETTERS
M1 - 106946
ER -